High Blood Pressure (Hypertension): Guidelines, Risks & Management

Hypertension is a leading modifiable risk factor for cardiovascular disease. Per ACC/AHA 2017 guidelines (endorsed by AHA), blood pressure categories are:

Blood Pressure Classification (Adults)

CategorySystolic (mmHg)Diastolic (mmHg)
Normal<120<80
Elevated120–129<80
Stage 1 HTN130–13980–89
Stage 2 HTN≥140≥90
Hypertensive Crisis>180>120

Major Health Risks of Uncontrolled HTN

  • Stroke (ischemic & hemorrhagic)—#1 risk factor
  • Myocardial infarction & heart failure
  • Chronic kidney disease & failure
  • Retinopathy & vision loss
  • Peripheral artery disease
  • Cognitive decline & dementia
  • Sexual dysfunction (erectile dysfunction, female sexual dysfunction)
  • Aortic aneurysm/dissection

Key Risk Factors

  • Non-modifiable: Age, family history, race (Black adults higher prevalence), chronic kidney disease.
  • Modifiable: Obesity, physical inactivity, high sodium/low potassium diet, excessive alcohol, smoking, stress, sleep apnea, diabetes, dyslipidemia.

Lifestyle Modifications (First-Line for All Stages)

InterventionTargetExpected SBP Reduction
DASH dietFruits, vegetables, low-fat dairy, whole grains, low sodium–11 mmHg
Sodium restriction<1,500 mg/day (ideal); <2,300 mg minimum–5 to –6 mmHg
Potassium increase3,500–5,000 mg/day (food sources)–4 to –5 mmHg
Weight lossBMI 18.5–24.9; waist <40" (M), <35" (F)–1 mmHg per kg lost
Physical activity≥150 min/wk moderate or 75 min/wk vigorous + resistance 2×/wk–5 to –8 mmHg
Alcohol moderation≤2 drinks/day (M), ≤1 (F)–4 mmHg
Smoking cessationCompleteCV risk reduction > BP effect
Stress managementMeditation, CBT, biofeedback, adequate sleepVariable

Pharmacologic Treatment

Indicated for:

  • Stage 1 HTN + ASCVD or 10-year ASCVD risk ≥10%
  • Stage 2 HTN
  • Any stage with diabetes, CKD, heart failure

First-Line Drug Classes

  • Thiazide/thiazide-like diuretics (chlorthalidone, indapamide)
  • ACE inhibitors (lisinopril, ramipril)
  • ARBs (losartan, valsartan)
  • Dihydropyridine CCBs (amlodipine)

Combination therapy often needed; single-pill combinations improve adherence.

Monitoring & Goals

  • Home BP monitoring: Validated device, proper technique, morning/evening readings, share with clinician.
  • Target: <130/80 mmHg for most adults (individualize for frailty, orthostasis, comorbidities).
  • Follow-up: Monthly until controlled, then 3–6 months.

Hypertension is a silent killer—often asymptomatic until complications arise. Regular screening, lifestyle change, and appropriate medication save lives.

Hypertension - Related Articles